Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1

Biochemical Pharmacology

Volumn 75, Issue 10, 2008, Pages 1924-1934

  Krishnan, Anand ^a   Hariharan, Ramkumar ^a   Nair, S Asha ^a   Pillai, M Radhakrishna ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Cell cycle arrest; CKS1; Docking; Fluoxetine; P27

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN E; CYCLOPHOSPHAMIDE; FLUOXETINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN P21; PROTEIN P27;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLOPHOSPHAMIDE; FEMALE; FIBROBLASTS; FLUOXETINE; G0 PHASE; G1 PHASE; HUMANS; RNA, MESSENGER; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 42649135555     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.02.013     Document Type: Article

References (42)

1. Wong D.T., Bymaster F.P., and Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57 (1995) 411-441
2. Peer D., and Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Lett 237 (2006) 180-187
3. Peer D., Dekel Y., Melikhov D., and Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64 (2004) 7562-7569
4. Abdul M., Logothetis C.J., and Hoosein N.M. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154 (1995) 247-250
5. Arimochi H., and Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 541 (2006) 17-23
6. Encinas J.M., Vaahtokari A., and Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 103 (2006) 8233-8238
7. Tsihlias J., Kapusta L., and Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 50 (1999) 401-423
8. Senderowicz A.M., and Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92 (2000) 376-387
9. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G 1-phase progression. Genes Dev 13 (1999) 1501-1512
10. Spruck C., Strohmaier H., Watson M., Smith A.P.L., Ryan A., Krek W., et al. A CDK-independent function of mammalian cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1. Mol Cell 7 (2001) 639-650
11. Bornstein G., Bloom J., Shevah D.S., Nakayama K., Pagano M., and Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21cip1 in S phase. J Biol Chem 278 (2003) 25752-25757
12. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2123-2714
13. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267 (1997) 727-748
14. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 52 (2003) 609-623
15. Gasteiger J., Rudolph C., and Sadowski J. Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Comp Method 3 (1990) 537-547
16. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 6 (2006) 392-401
17. Amato P., and Carpenter J.S. Fluoxetine may reduce hot flashes in women with a history of breast cancer. Evidence-based Oncol 3 (2002) 182-184
18. Chhipa R.R., Singh S., Surve S.V., Vijayakumar M.V., and Bhat M.K. Doxycycline potentiates antitumor effect of cyclophosphamide in mice. Toxicol Appl Pharmacol 202 (2005) 268-277
19. Wang K., Shindoh H., Inoue T., and Horii I. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J Toxicol Sci 27 (2002) 229-237
20. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma. Blood 101 (2003) 3212-3219
21. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
22. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., and Ford R.J. Inhibition of constitutive NFκB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171 (2003) 88-95
23. Yan J., Luo D., Luo Y., Gao X., and Zhang G. Induction of G1 arrest and differentiation in MDA-MB-231 breast cancer cell by boehmeriasin A, a novel compound from plant. Int J Gynecol Cancer 16 (2006) 165-170
24. Krishnan A., Nair S.A., and Pillai M.R. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 6 (2007) 532-540
25. Ganoth D., Bornstein G., Ko T.K., Larsen B., Tyers M., Pagano M., et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3 (2001) 321-324
26. Harper J.W. Protein destruction: adapting roles for CKS proteins. Curr Biol 11 (2001) 431-435
27. Kitajima S., Kudo Y., Ogawa I., Bashir T., Kitagawa M., and Miyauchi M. Role of Cks1 overexpression in oral squamous cell carcinomas. Cooperation with Skp2 in promoting p27 degradation. Am J Pathol 165 (2004) 2147-2155
28. Slotky M., Shapira M., Ben-Izhak O., Linn S., Futerman B., and Tsalic M. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 7 (2005) 737-744
29. Masuda T., Inoue H., Nishida K., Sonoda H., Yoshikawa Y., and Kakeji Y. Cyclin dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 9 (2003) 5693-5698
30. Sitry D., Seeliger M.A., Ko T.K., Ganoth D., Breward S.E., and Itzhaki L.S. Three different binding sites of cks1 are required for p27-ubiquitin ligation. J Biol Chem 277 (2002) 42233-42240
31. Ungermannova D., Gao Y., and Liu X. Ubiquitination of p27kip1 requires physical interaction with cyclin E and probable phosphate recognition by skp2. J Biol Chem 280 (2005) 30301-30309
32. Leon D., Albasanz J.L., Rui{dotless}z M.A., Fernandez M., and Marti{dotless}n M. Adenosine A1 receptor down-regulation in mothers and fetal brain after caffeine and theophylline treatments to pregnant rats. J Neurochem 82 (2002) 625-634
33. Leysen J.E., Gommeren W., Janssen P.F., Gompel P.V., and Janssen P.A. Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation. Psychopharmacol Ser 5 (1988) 12-26
34. cdc28/cdc2-associated protein of Saccharomyces cerevisiae and Schizosac charomyces pombe. Genes Dev 4 (1990) 1332-1344
35. Hattori T., Kitagawa K., Uchida C., Oda T., and Kitagawa M. Cks1 is degraded via the ubiquitin-proteasome pathway in a cell cycle-dependent manner. Genes Cells 8 (2003) 889-896
36. Singer J.D., Gurian-West M., Clurman B., and Roberts J.M. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 13 (1999) 2375-2387
37. Wang Y., Penfold S., Tang X., Hattori N., Riley P., and Harper J.W. Deletion of the Cul1 gene in mice causes arrest in early embryogenesis and accumulation of cyclin E. Curr Biol 9 (1999) 1191-1194
38. Won K.A., and Reed S.I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 15 (1996) 4182-4193
39. Nakayama K., Nagahama H., Minamishima Y.A., Matsumoto M., Nakamichi I., Kitagawa K., et al. Targeted disruption of skp2 results in accumulation of cyclin E and p27kip1, polyploidy and centrosome overduplication. EMBO J 19 (2000) 2069-2081
40. Halfter H., Friedrich M., Resch A., Kullmann M., Stogbauer F., Ringelstein E.B., et al. Oncostatin M induces growth arrest by inhibition of skp2, cks1, and cyclin A expression and induced p21 expression. Cancer Res 66 (2006) 6530-6539
41. Lietoa A.D., Leoa D., Volpicellia F., Porzioa U., and Colucci-D'Amatoa L. Fluoxetine modifies the expression of serotonergic markers in a differentiation-dependent fashion in the mesencephalic neural cell line A1 mes c-myc. Brain Res 1143 (2007) 1-10
42. Lawlor D., Juni A.P., Ebrahim S., and Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 56 (2003) 155-163